Metformin and Testosterone Interaction: Compatible | Peptide Database

FDA-approved first-line treatment for excessive daytime sleepiness associated with narcolepsy. Significantly reduces unintended sleep episodes and improves the ability to sustain wakefulness throughout the day. FDA-approved for excessive sleepiness in individuals who work non-traditional hours (night shifts, rotating shifts). Taken 1 hour before the start of the work shift to maintain alertness during the shift. FDA-approved as adjunctive therapy for residual excessive daytime sleepiness in patients with obstructive sleep apnea who are already using CPAP but still experience daytime somnolence. Does not treat the underlying airway obstruction. Well-documented improvements in sustained attention, vigilance, and concentration during prolonged tasks. Benefits are most pronounced under conditions of sleep deprivation or fatigue, but also observed in well-rested individuals performing demanding cognitive work. Improvements in planning, decision-making, and cognitive flexibility observed across multiple studies. Effects are more consistent and reliable in sleep-deprived populations than in well-rested individuals. Modest improvements in working memory tasks, particularly in individuals experiencing fatigue or sleep deficit. Effects in well-rested, high-baseline individuals are less consistent. Used off-label for attention-deficit/hyperactivity disorder. Some studies show improvements in attention and impulsivity comparable to methylphenidate, though modafinil is not FDA-approved for this indication. FDA declined approval for pediatric ADHD due to skin reaction concerns. Investigated as an adjunct to antidepressants for treatment-resistant fatigue and cognitive symptoms in major depressive disorder. May improve residual sleepiness and cognitive dullness that persist despite adequate antidepressant response. Used off-label for fatigue associated with multiple sclerosis, one of the most disabling symptoms of the disease. Evidence is mixed, with some patients reporting meaningful improvement in energy and daily functioning.

Treatment of overt and subclinical hypothyroidism, either as monotherapy or in combination with levothyroxine (T4). Particularly useful in patients who report persistent symptoms despite normalized TSH on T4 monotherapy, suggesting poor peripheral conversion. Emergency treatment of severe hypothyroidism presenting as myxedema coma. Intravenous T3 is preferred due to its rapid onset of action compared to T4. Supplementation in individuals with documented poor conversion of T4 to T3 due to deiodinase polymorphisms (DIO2 gene variants), chronic caloric restriction, illness, or elevated reverse T3 levels. Diagnostic use in thyroid suppression tests to differentiate between types of thyroid autonomy. Widely used in bodybuilding and physique sports to accelerate fat loss during caloric deficit. T3 increases basal metabolic rate by 10-15% at moderate doses, promoting faster utilization of stored fat. Most effective when combined with adequate protein intake and resistance training to minimize muscle catabolism. Used by biohackers and longevity-focused individuals to maintain optimal metabolic rate, particularly during extended caloric restriction, reverse dieting, or in the context of metabolic adaptation (adaptive thermogenesis). Standard component of bodybuilding contest prep stacks, typically combined with anabolic steroids (to offset catabolism) and beta-2 agonists for maximal fat mobilization in the final 6-8 weeks before competition.